Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Lupus. 2022 Mar 8;31(4):472–481. doi: 10.1177/09612033221084093

Table 1.

Epidemiologic characteristics of the study population according to treatment response to antimalarials

HCQ Responders (n=22) HCQ + QC Responders (n = 24) Nonresponders (n = 19) p-value
Age, y, mean +/− SEM 52.2 +/− 4.5 45.4 +/− 2.8 40.8 +/− 2.3 0.05
Sex, n (%) ns
 Male 3 (13.6) 3 (12.5) 4 (21.1)
 Female 19 (86.4) 21 (87.5) 15 (78.9)
Race, n (%) ns
 Caucasian 14 (63.6) 15 (62.5) 11 (57.9)
 African American 5 (22.7) 8 (33.3) 5 (26.3)
 Asian 0 (0) 0 (0) 1 (5.3)
 Other 1 (4.5) 1 (4.2) 2 (10.5)
 Unknown 2 (9.1) 0 (0) 0 (0)
Smoking Status ns
 Current 7 (31.8) 7 (29.2) 6 (31.6)
 Former 5 (22.7) 2 (8.3) 3 (15.8)
 Never 9 (40.1) 13 (54.2) 10 (52.6)
 Unknown 1 (4.5) 2 (8.3) 0 (0)
CLASI-Activity score, mean +/− SEM 11.5 +/− 2.6 (n=16) 12.6 +/− 2.3 (n=19) 18.3 +/− 2.8 (n=18) ns
CLE subtypes, n (%) ns
 ACLE 0 (0) 0 (0) 2 (10.5)
 SCLE 10 (45.5) 9 (37.5) 8 (42.1)
 DLE 11 (50.0) 15 (62.5) 9 (47.4)
 LET 2 (9.9) 0 (0) 1 (5.3)
Associated SLE, n (%) ns
 Present 7 (31.8) 9 (37.5) 2 (10.5)
 Absent 15 (68.2) 15 (62.5) 17 (89.5)?
Cicatricial alopecia, n (%) ns
 Present 5 (22.7) 12 (50) 8 (42.1)
 Absent 14 (63.6) 9 (37.5) 10 (52.6)
 Unknown 3 (13.6) 3 (12.5) 1 (5.3)
Disseminated DLE, n (%) ns
 Present 3 (13.6) 6 (25) 5 (26.3)
 Absent 19 (86.4) 18 (75) 14 (73.7)
Hypertrophic DLE. n (%) ns
 Present 1 (4.5) 2 (8.3) 1 (5.3)
 Absent 21 (95.5) 22 (91.7) 18 (94.7)